FDA shares additional draft guidance on CGTs
The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.
Corporate Governance
Trump 2.0 spells uncertainty for US healthcare, says analyst
Zentiva voices UWWTD concerns as EU grants approval
FDA approves Journey Medical’s rosacea treatment Emrosi
NCCN visits Vietnam in continued cancer care collaboration
Reeves’ 2024 budget promises life sciences investment
Global conflicts prompt GPEI to delay polio eradication target
mRNA licensing agreements surge 800% amid GSK lawsuits
